Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
Immix Biopharma (IMMX) has announced a conference call scheduled for Tuesday, December 10, 2024, at 4:30 p.m. Eastern Time. The call will feature company management providing updates on positive new developments regarding CAR-T NXC-201 in relapsed/refractory AL Amyloidosis.
The clinical-stage biopharmaceutical company, which focuses on developing cell therapies for AL Amyloidosis and select immune-mediated diseases, will host the call via Zoom. Following management's formal presentation, attendees will have the opportunity to participate in a question-and-answer session.
Immix Biopharma (IMMX) ha annunciato una conferenza telefonica programmata per martedì 10 dicembre 2024, alle 16:30 ora dell'Est. La chiamata presenterà la gestione dell'azienda che fornirà aggiornamenti su nuovi sviluppi positivi riguardanti CAR-T NXC-201 nell'amiloidosi AL recidivante/refrattaria.
La società biofarmaceutica in fase clinica, che si concentra sullo sviluppo di terapie cellulari per l'amiloidosi AL e alcune malattie immunomediate selezionate, ospiterà la chiamata tramite Zoom. Dopo la presentazione formale della gestione, i partecipanti avranno l'opportunità di partecipare a una sessione di domande e risposte.
Immix Biopharma (IMMX) ha anunciado una llamada de conferencia programada para el martes 10 de diciembre de 2024, a las 4:30 p.m. hora del Este. En la llamada, la dirección de la empresa proporcionará actualizaciones sobre nuevos desarrollos positivos relacionados con CAR-T NXC-201 en la amiloidosis AL recidivante/refractaria.
La empresa biofarmacéutica en etapa clínica, que se centra en desarrollar terapias celulares para la amiloidosis AL y algunas enfermedades mediadas por el sistema inmunológico, llevará a cabo la llamada a través de Zoom. Tras la presentación formal de la dirección, los asistentes tendrán la oportunidad de participar en una sesión de preguntas y respuestas.
Immix Biopharma (IMMX)는 2024년 12월 10일 화요일 동부 표준시 기준 오후 4시 30분에 예정된 전화 회의를 발표했습니다. 이번 회의는 회사 경영진이 재발/불응성 AL 아밀로이드증에 대한 CAR-T NXC-201의 긍정적인 새로운 발전에 대한 업데이트를 제공할 것입니다.
임상 단계의 바이오제약 회사는 AL 아밀로이드증 및 선택된 면역 매개 질환에 대한 세포 치료제 개발에 집중하고 있으며, Zoom을 통해 회의를 주최합니다. 경영진의 공식 발표 후 참석자들은 질문 및 답변 세션에 참여할 기회를 갖게 됩니다.
Immix Biopharma (IMMX) a annoncé une conférence téléphonique programmée pour le mardi 10 décembre 2024, à 16h30 heure de l'Est. L'appel mettra en vedette la direction de l'entreprise fournissant des mises à jour sur de nouveaux développements positifs concernant CAR-T NXC-201 dans l'amyloïdose AL récidivante/réfractaire.
La société biopharmaceutique en phase clinique, qui se concentre sur le développement de thérapies cellulaires pour l'amyloïdose AL et certaines maladies immunomédiées sélectionnées, animera l'appel via Zoom. À l'issue de la présentation formelle de la direction, les participants auront l'opportunité de participer à une séance de questions-réponses.
Immix Biopharma (IMMX) hat eine Telefonkonferenz für Dienstag, den 10. Dezember 2024, um 16:30 Uhr Eastern Time angekündigt. In dem Gespräch wird das Management des Unternehmens Aktualisierungen zu positiven neuen Entwicklungen bezüglich CAR-T NXC-201 bei rezidivierenden/refraktären AL-Amyloidose bereitstellen.
Das biopharmazeutische Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Zelltherapien für AL-Amyloidose und ausgewählte immunvermittelte Erkrankungen konzentriert, wird die Konferenz über Zoom abhalten. Nach der formalen Präsentation des Managements haben die Teilnehmer die Möglichkeit, an einer Frage- und Antwortsitzung teilzunehmen.
- None.
- None.
- Company management will provide an update on positive new developments regarding CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. Following management’s formal remarks, there will be a question-and-answer session.
- Conference Call to be held Tuesday, December 10, 2024 at 4:30 p.m. Eastern Time
- Interested parties can attend the conference call via Zoom using the following link: https://zoom.us/j/94736340854?pwd=LTBtu2LuvwSb6S6ISuH5yKTDLsI2vt.1
LOS ANGELES, CA, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, announced that it will hold a conference call for investors, analysts and members of the media on Tuesday, December 10, 2024 at 4:30 p.m. Eastern Time.
Company management will provide an update on positive new developments regarding CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. Following management’s formal remarks, there will be a question-and-answer session.
Interested parties can attend the conference call via Zoom using the following link:
https://zoom.us/j/94736340854?pwd=LTBtu2LuvwSb6S6ISuH5yKTDLsI2vt.1
About NXC-201
NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy. Initial data from Phase 1b/2 ex-U.S. study NEXICART-1 has demonstrated robust clinical responses with no neurotoxicity of any kind in relapsed/refractory AL Amyloidosis.
NXC-201 is being studied in a comprehensive clinical development program for the treatment of patients with relapsed/refractory AL amyloidosis, with the potential to expand into select immune-mediated diseases. The NXC-201 NEXICART-2 (NCT06097832) U.S. clinical trial builds on a robust clinical dataset. NXC-201 has been awarded Orphan Drug Designation (ODD) in AL Amyloidosis by the US FDA and in the EU by the EMA.
About AL Amyloidosis
AL amyloidosis is caused by abnormal plasma cells in the bone marrow, which produce misfolded amyloid proteins that build-up in the heart, kidney, liver, and other organs. This build-up causes progressive and widespread damage to multiple organs, including heart failure, and leads to high mortality rates.
The U.S. observed prevalence of relapsed/refractory AL Amyloidosis is estimated to be growing at
The Amyloidosis market was
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. NXC-201 is being evaluated in the U.S. Phase 1b/2 trial NEXICART-2 (NCT06097832) as well as the ex-U.S. study NEXICART-1 (NCT04720313). NXC-201 has demonstrated no neurotoxicity of any kind in AL Amyloidosis and short duration of cytokine release syndrome (CRS), supporting expansion into select immune-mediated diseases. NXC-201 has been awarded Orphan Drug Designation (ODD) in AL Amyloidosis by the US FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com.
Forward Looking Statements
This press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the receipt of, timing of receipt, finalization of the terms of, and allocation of funds in connection with, the grant discussed above and potential benefits of our product candidate CAR-T NXC-201. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1b/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the initial data initial data readouts, (ii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iii) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (iv) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (v) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 29, 2024 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Company Contact
irteam@immixbio.com
FAQ
When is Immix Biopharma (IMMX) hosting its conference call about CAR-T NXC-201?
What will be discussed in the IMMX December 2024 conference call?
How can investors join the IMMX December 2024 conference call?
What type of therapy is IMMX developing for AL Amyloidosis?
